Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in patients with atrial fibrillation: from asian perspectives
Which factors recorded during routine care predict treatment discontinuation of novel oral anticoagulants in patients with non-valvular atrial fibrillation?